Mayinglong Pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 27.96%

Mayinglong Pharmaceutical Group Co Ltd (600993) has an Asset Resilience Ratio of 27.96% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Mayinglong Pharmaceutical Group Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥1.58 Billion

≈ $230.71 Million USD Cash + Short-term Investments

Total Assets

CN¥5.64 Billion

≈ $825.21 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2001–2025)

This chart shows how Mayinglong Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Mayinglong Pharmaceutical Group Co Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Mayinglong Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 600993 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥1.58 Billion	27.96%
Total Liquid Assets	CN¥1.58 Billion	27.96%

Asset Resilience Insights

Very High Liquidity: Mayinglong Pharmaceutical Group Co Ltd maintains exceptional liquid asset reserves at 27.96% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Mayinglong Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Mayinglong Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shan Dong Dong-E E-Jiao Co Ltd SHE:000423	Drug Manufacturers - Specialty & Generic	20.44%
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	Drug Manufacturers - Specialty & Generic	47.16%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Piramal Pharma Limited NSE:PPLPHARMA	Drug Manufacturers - Specialty & Generic	0.73%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%

Annual Asset Resilience Ratio for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)

The table below shows the annual Asset Resilience Ratio data for Mayinglong Pharmaceutical Group Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	9.31%	CN¥506.09 Million ≈ $74.06 Million	CN¥5.44 Billion ≈ $795.49 Million	+6.57pp
2024-12-31	2.74%	CN¥142.14 Million ≈ $20.80 Million	CN¥5.18 Billion ≈ $758.28 Million	+1.43pp
2023-12-31	1.31%	CN¥63.29 Million ≈ $9.26 Million	CN¥4.83 Billion ≈ $706.71 Million	-12.02pp
2022-12-31	13.33%	CN¥674.35 Million ≈ $98.68 Million	CN¥5.06 Billion ≈ $740.09 Million	+10.76pp
2021-12-31	2.57%	CN¥106.02 Million ≈ $15.51 Million	CN¥4.13 Billion ≈ $603.90 Million	+1.63pp
2020-12-31	0.94%	CN¥36.32 Million ≈ $5.31 Million	CN¥3.87 Billion ≈ $565.78 Million	-1.93pp
2019-12-31	2.87%	CN¥94.32 Million ≈ $13.80 Million	CN¥3.29 Billion ≈ $480.76 Million	+0.11pp
2018-12-31	2.77%	CN¥80.93 Million ≈ $11.84 Million	CN¥2.93 Billion ≈ $428.24 Million	-4.79pp
2017-12-31	7.55%	CN¥208.00 Million ≈ $30.44 Million	CN¥2.75 Billion ≈ $402.99 Million	+6.71pp
2016-12-31	0.85%	CN¥21.17 Million ≈ $3.10 Million	CN¥2.50 Billion ≈ $365.35 Million	-0.35pp
2015-12-31	1.20%	CN¥28.81 Million ≈ $4.22 Million	CN¥2.41 Billion ≈ $352.64 Million	-1.19pp
2014-12-31	2.38%	CN¥52.05 Million ≈ $7.62 Million	CN¥2.19 Billion ≈ $319.83 Million	+0.41pp
2013-12-31	1.97%	CN¥39.98 Million ≈ $5.85 Million	CN¥2.03 Billion ≈ $296.68 Million	-0.06pp
2012-12-31	2.03%	CN¥37.37 Million ≈ $5.47 Million	CN¥1.84 Billion ≈ $269.67 Million	-3.47pp
2011-12-31	5.49%	CN¥91.07 Million ≈ $13.33 Million	CN¥1.66 Billion ≈ $242.56 Million	+1.34pp
2010-12-31	4.15%	CN¥60.12 Million ≈ $8.80 Million	CN¥1.45 Billion ≈ $212.02 Million	+1.42pp
2009-12-31	2.73%	CN¥39.15 Million ≈ $5.73 Million	CN¥1.44 Billion ≈ $210.11 Million	-10.32pp
2008-12-31	13.05%	CN¥151.74 Million ≈ $22.20 Million	CN¥1.16 Billion ≈ $170.17 Million	+9.31pp
2007-12-31	3.74%	CN¥40.84 Million ≈ $5.98 Million	CN¥1.09 Billion ≈ $159.74 Million	+3.61pp
2006-12-31	0.13%	CN¥1.45 Million ≈ $211.62K	CN¥1.11 Billion ≈ $161.80 Million	+0.12pp
2003-12-31	0.01%	CN¥50.59K ≈ $7.40K	CN¥367.95 Million ≈ $53.84 Million	-0.15pp
2002-12-31	0.16%	CN¥580.07K ≈ $84.88K	CN¥363.13 Million ≈ $53.14 Million	+0.11pp
2001-12-31	0.05%	CN¥151.42K ≈ $22.16K	CN¥320.89 Million ≈ $46.96 Million	--

pp = percentage points

About Mayinglong Pharmaceutical Group Co Ltd

SHG:600993 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.43 Billion

CN¥9.77 Billion CNY

Market Cap Rank

#7458 Global

#1631 in China

Share Price

CN¥22.67

Change (1 day)

+1.07%

52-Week Range

CN¥21.55 - CN¥30.12

All Time High

CN¥31.68